当前与数十年前食管腺癌表型及危险因素比较
该单中心回顾性队列研究比较了1996-1997年与2009-2012年两个时期食管腺癌患者的危险因素、表型比例和生存期。结果显示两时期患者在年龄、性别、吸烟史、反流症状缺失比例、肠化生比例及肿瘤分期上均无显著差异,但1996-1997年诊断与死亡风险增加独立相关。
要点
- 两时期食管腺癌患者均约半数无反流症状,肠化生比例相似,提示肿瘤表型持续存在。
- 1996-1997年诊断者死亡风险较2009-2012年显著增高,校正后风险比1.7。
- 多数患者确诊时已为III期,提示早期识别仍困难。
核心结论
- 两时期食管腺癌的表型(肠化生/非肠化生比例)和无症状比例持续相似,1996-1997年诊断与更高死亡风险独立相关。
研究设计与样本
- 单中心回顾性队列研究,纳入829例食管腺癌患者,比较1996-1997年(149例)与2009-2012年(680例)两个时期。
主要发现
- 两时期患者年龄、性别、吸烟史无显著差异(P > .05)。
- 无反流症状者比例两时期相近(P = .46)。
- 肠化生比例1996-1997年为48.3%,2009-2012年为49.9%(P = .45)。
- 肿瘤分期分布相似(P = .25),III期占43%(1996-1997)和37.8%(2009-2012)。
- 1996-1997年诊断与死亡风险增加相关:单变量HR 1.6(95%CI 1.3-2.0,P = .001),多变量校正后HR 1.7(95%CI 1.4-2.1,P < .001)。
关键数值与推荐
- 肠化生比例:1996-1997年48.3% vs 2009-2012年49.9%(P = .45)。
- III期比例:1996-1997年43% vs 2009-2012年37.8%(P = .25)。
- 死亡风险:1996-1997年 vs 2009-2012年,校正后HR 1.7(95%CI 1.4-2.1,P < .001)。
临床怎么用
- 食管腺癌患者中近半数无反流症状,不能仅依赖症状筛查。
- 肠化生比例未随时间变化,提示非肠化生通路可能持续贡献食管腺癌发生。
- 多数患者确诊时已为III期,需探索更有效的早期识别策略。
局限性
- 单中心回顾性研究,可能存在选择偏倚。
- 样本来自两个特定时间段,结果外推需谨慎。
- 未报告其他潜在混杂因素(如 Barrett 食管筛查、治疗方式等)的调整情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The incidence of esophageal adenocarcinoma (EAC) has increased over the past decades. It is unclear if this increase is the result of a new cancer phenotype or an increase in risk factors for EAC. We aimed to compare risk factors, the proportions of intestinal and nonintestinal phenotypes of EAC, and survival times of patients during the 2009 to 2012 time period vs the 1996 to 1997 time period. METHODS: We performed a retrospective single-center cohort study of 829 patients with EAC from the time periods of 1996 to 1997 and 2009 to 2012. Baseline characteristics were compared using χ2 analysis for categoric variables and the Student t test for continuous variables. The Cox proportional hazards model was used to compare 5-year survival. RESULTS: We included 149 patients from the 1996 to 1997 time period and 680 patients from the 2009 to 2012 time period. There was no significant difference between the cohorts in terms of age at cancer presentation, sex, or history of smoking (P > .05). Gastroesophageal reflux symptoms were absent in almost half of the patients from each time period (P = .46). Intestinal metaplasia was identified in esophageal tumor tissues from 48.3% of patients with EAC in the 1996 to 1997 time period and in 49.9% of patients in the 2009 to 2012 time period (P = .45). Patients from each time period presented with similar-stage cancer (P = .25), most at stage III (43% in the 1996-1997 period and 37.8% in the 2009-2012 period). Having EAC during the period of 1996 to1997 was associated with an increased risk of death (hazard ratio, 1.6; 95% CI, 1.3-2.0; P = .001), compared with the 2009 to 2012 time period, in a univariate model (adjusted hazard ratio, 1.7; 95% CI, 1.4-2.1; P < .001) after we controlled for sex, age at diagnosis, tumor stage, and presence of intestinal metaplasia. CONCLUSIONS: In a comparison of patients with EAC from the time periods of 1996 to 1997 vs 2009 to 2012, we found similar and persistent proportions of tumor phenotypes, characterized by a lack of intestinal metaplasia or heartburn symptoms. The lack of symptoms could contribute to our continued inability to identify incident cancers and/or improve patient survival.
引用
- Sawas T, Azad N, Killcoyne S, et al. Comparison of Phenotypes and Risk Factors for Esophageal Adenocarcinoma at Present vs Prior Decades. Clin Gastroenterol Hepatol. 2019. PMID: 31712077. doi:10.1016/j.cgh.2019.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。